Target intelligence / Profile preview

Eukaryotic translation termination factor 1 (eRF1)

Target
eRF1
Molecular classification
Other (Translation factor), Peptide termination factor, Class 1 polypeptide chain release factor
01

Overview

Eukaryotic translation termination factor 1 (eRF1) is an essential protein involved in the recognition of stop codons (UAA, UAG, UGA) during mRNA translation, and catalyzes the release of newly synthesized polypeptides from the ribosome. eRF1 functions as part of a complex with eRF3 and GTP, and is required for accurate termination of translation and for nonsense-mediated mRNA decay (NMD), which eliminates mRNAs with premature stop codons. The structure of eRF1 consists of three domains that collectively mimic tRNA, allowing eRF1 to fit into the ribosomal A-site and interact with the peptidyl transferase center to hydrolyze peptidyl-tRNA. Proper functioning of eRF1 is critical for cellular viability, with mutations in key motifs (such as the GGQ loop) leading to loss of function and cell death. eRF1 is highly conserved among eukaryotes and has functional homologs in archaea, with distinct evolutionary differences from prokaryotic release factors[1][2][3].

Other names
TB3-1SUP45L1ETF1ERF1
02

Biological functions

Termination of translationStop codon recognitionNonsense-mediated mRNA decayPeptidyl-tRNA hydrolysis
03

Disease associations

Other (no direct major roles in cancer, inflammation, neurodegeneration, etc. documented in the sources; associated with rare diseases such as Human Monocytic Ehrlichiosis)
04

Safety considerations

Mutations in eRF1 can be lethal to cells due to failure of translation termination. Disruption can lead to production of aberrant proteins[1][2]

Beyond the preview

Go deeper on Eukaryotic translation termination factor 1 (eRF1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eukaryotic translation termination factor 1 (eRF1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call